Publications and communications of SERVAIS, Sophie

GREGOIRE, C., SERVAIS, S., WILLEMS, E., BAUDOUX, E., LECHANTEUR, C., BRIQUET, A., Bettonville, V., DETRY, O., ERPICUM, P., JOURET, F., LOUIS, E., BARON, F., & BEGUIN, Y. (April 2022). Immunothérapie cellulaire au CHU de Liège : avancées, défis et perspectives. Revue Médicale de Liège, 77 (4), 206-211.

Canti, L.* , Humblet-Baron, S.* , Desombere, I., Neumann, J., Pannus, P., Heyndrickx, L., Henry, A., SERVAIS, S., WILLEMS, E., Ehx, G., Goriely, S., Seidel, L., Michiels, J., Willems, B., Liston, A., Ariën, K. K., Beguin, Y., Goossens, M. E., Marchant, A., & Baron, F. (2021). Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients. Journal of hematology & oncology, 14 (1), 174. doi:10.1186/s13045-021-01190-3

Catalano, C., SERVAIS, S., BONVOISIN, C., Couturier, B., Hildebrand, M., Etienne, I., MEURIS, C., Goffard, J.-C., Wissing, M., Goldman, M., & Le Moine, A. (2021). Preemptive Antibody Therapy for Vaccine Breakthrough SARS-CoV-2 Infection in Immunocompromised Patients. Transplantation, 105, 282. doi:10.1097/TP.0000000000003942

Courtois, J., Ritacco, C., DUBOIS, S., Canti, L., Vandenhove, B., SEIDEL, L., Daulne, C., CAERS, J., SERVAIS, S., Beguin, Y., Ehx, G., & BARON, F. (2021). Itacitinib prevents xenogeneic GVHD in humanized mice. Bone Marrow Transplantation, 56, 2672-2681. doi:10.1038/s41409-021-01363-1

Ehx, G., Ritacco, C., HANNON, M., DUBOIS, S., Delens, L., WILLEMS, E., SERVAIS, S., Drion, P., BEGUIN, Y., & Baron, F. (2021). Comprehensive analysis of the immunomodulatory effects of rapamycin on human T cells in graft-versus-host disease prophylaxis. American Journal of Transplantation, 21, 2662-2674. doi:10.1111/ajt.16505

MAQUET, C., BEGUIN, Y., DE PRIJCK, B., WILLEMS, E., SERVAIS, S., & BONNET, C. (2021). Le lymphome diffus à grandes cellules B : nouveau traitement révolutionnaire par des cellules immunitaires génétiquement modifiées appelées «CAR T cells». Revue Médicale de Liège, 76, 476-481.

Narinx, J., SERVAIS, S., BARON, F., BEGUIN, Y., & WILLEMS, E. (2021). Allogreffes de cellules souches hématopoïétiques : principes généraux et progrès récents. Revue Médicale de Liège, 76, 464-469.

Ritacco, C., Ehx, G., GREGOIRE, C., Daulne, C., WILLEMS, E., SERVAIS, S., BEGUIN, Y., & Baron, F. (2021). High proportion of terminally-differentiated regulatory T cells after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 56, 1828-1841. doi:10.1038/s41409-021-01221-0

Rubio, M., Varlet, P., Allain, V., Ballot, C., Cuffel, A., Deschamps, M., Ferrand, C., FOGUENNE, J., Forcade, E., Huynh, A., Guihot, A., Latouche, J.-B., Lemarie, C., Martinroche, G., Morin, F., Nguyen, S., SCHMIT, K., SERVAIS, S., Simonetta, F., & Zucman, S. (2021). Suivi immunologique des patients traités par cellules CAR-T pour hémopathie maligne: recommandations du groupe CARTi et de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)Immunomonitoring of patients treated with CAR-T cells for hematological malignancy: Guidelines from the CARTi group and the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Bulletin du Cancer, 108, 53-S64. doi:10.1016/j.bulcan.2021.04.008

Delens, L., Ehx, G., SOMJA, J., Vrancken, L., Belle, L., SEIDEL, L., Grégoire, C., Fransolet, G., Ritacco, C., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & Servais, S. (2019). In Vitro Th17-Polarized Human CD4(+) T Cells Exacerbate Xenogeneic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 25, 204-215. doi:10.1016/j.bbmt.2018.10.007

Grégoire, C., Ritacco, C., Hannon, M., SEIDEL, L., Delens, L., Belle, L., DUBOIS, S., Veriter, S., LECHANTEUR, C., BRIQUET, A., Servais, S., Ehx, G., Beguin, Y., & Baron, F. (2019). Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model. Frontiers in Immunology, 10, 619. doi:10.3389/fimmu.2019.00619

Pirotte, M., Forte, F., Lutteri, L., WILLEMS, E., DURAN, U., Belle, L., Baron, F., BEGUIN, Y., Maquet, P., BODART, O., & Servais, S. (2018). Neuronal surface antibody-mediated encephalopathy as manifestation of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Journal of Neuroimmunology, 323, 115-118. doi:10.1016/j.jneuroim.2018.08.003

SERVAIS, S., Hannon, M., Peffault de Latour, R., Socie, G., & BEGUIN, Y. (2017). Reconstitution of adaptive immunity after umbilical cord blood transplantation and clinical implication regarding risk of infections. Stem Cell Investigation, 4, 40.

Vrancken, L., Delens, L., BEGUIN, Y., BARON, F., & SERVAIS, S. (2017). Focus sur les lymphocytes T dans la maladie du greffon contre l'hôte après allogreffe de cellules soucges hématopoïétiques: implications pour de nouvelles stratégies de prévention. Onco: Revue Multidisciplinaire d'Oncologie, 11, 23-31.

SERVAIS, S., BEGUIN, Y., Delens, L., Ehx, G., Fransolet, G., Hannon, M., WILLEMS, E., Humblet-Baron, S., Belle, L., & Baron, F. (11 May 2016). Novel approaches for preventing acute graftversus- host disease after allogeneic hematopoietic stem cell transplantation. Expert Opinion on Investigational Drugs, 9, 957-972. doi:10.1080/13543784.2016.1182498

SERVAIS, S., GREGOIRE, C., BARON, F., WILLEMS, E., BRIQUET, A., BAUDOUX, E., DELLOYE, O., GIET, O., LECHANTEUR, C., & BEGUIN, Y. (2016). Multipotent mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Belgian Journal of Hematology, 7, 229-235.

HANNON, M., BEGUIN, Y., Ehx, G., SERVAIS, S., SEIDEL, L., Graux, C., Maertens, J., Kerre, T., Daulne, C., de Bock, M., Fillet, M., ORY, A., WILLEMS, E., GOTHOT, A., Humblet-Baron, S., & BARON, F. (15 July 2015). Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation following Flu-TBI versus TLI-ATG Conditioning. Clinical Cancer Research, 21 (14), 3131-9. doi:10.1158/1078-0432.CCR-14-3374

SERVAIS, S., Menten-Dedoyart, C., Beguin, Y., SEIDEL, L., Gothot, A., Daulne, C., WILLEMS, E., Delens, L., Humblet-Baron, S., Hannon, M., & Baron, F. (2015). Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation. PLoS ONE, 10 (6), 0130026. doi:10.1371/journal.pone.0130026

JASPERS, A., BARON, F., MAERTENS, J., DE PRIJCK, B., SCHOTS, H., BONNET, C., HAFRAOUI, K., WILLEMS, E., SERVAIS, S., FILLET, G., & BEGUIN, Y. (December 2014). Long-term safety follow-up of a rendomized trial of Darbepoetin Alpha and intravenous iron following autologous hematopoietic cell transplantation. Blood, 124 (21), 3948.

Baron, F., Humblet-Baron, S., Ehx, G., SERVAIS, S., HANNON, M., Belle, L., LECHANTEUR, C., BRIQUET, A., GIET, O., BAUDOUX, E., WILLEMS, E., & Beguin, Y. (2014). Thinking out of the box - New approaches to controlling GVHD. Current Hematologic Malignancy Reports, 9, 73-84. doi:10.1007/s11899-013-0187-9

BEGUIN, Y., Maertens, J., DE PRIJCK, B., Schots, R., Seidel, L., BONNET, C., HAFRAOUI, K., WILLEMS, E., Vanstraelen, G., SERVAIS, S., JASPERS, A., FILLET, G., & BARON, F. (2013). Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation : A prospective multicenter randomized trial. American Journal of Hematology, 88, 990-996. doi:10.1002/ajh.23552

SERVAIS, S., Beguin, Y., & Baron, F. (2013). Emerging drugs for prevention of graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opinion on Emerging Drugs, 18 (2), 173-192. doi:10.1517/14728214.2013.798642

SERVAIS, S., WILLEMS, E., Beguin, Y., & Baron, F. (2013). Allogreffe de cellules souches hématopoïétiques chez le patient âgé : jusqu'à quel âge ? Revue Médicale de Liège, 68 (1), 38-43.

SERVAIS, S., Hannon, M., Daulne, C., Gothot, A., Beguin, Y., & Baron, F. (February 2012). Longitudinal Monitoring of Immune Reconstitution after Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT): Impact of T-Cell Depletion of the Graft. Biology of Blood and Marrow Transplantation, 18 (2), 274-S275. doi:10.1016/j.bbmt.2011.12.193

Baron, F., & SERVAIS, S. (2012). Rituximab et maladie du greffon contre l'hôte chronique. Horizons Hemato, 2 (2), 78-81.

FRUSCH, N., SERVAIS, S., DE PRIJCK, B., Corhay, J.-L., Beguin, Y., Louis, R., & DUYSINX, B. (2012). Spontaneous pneumomediastinum caused by bleomycin-induced pneumonitis. Acta Clinica Belgica, 67-68. doi:10.2143/ACB.67.5.2062693

Malaise, O., FRUSCH, N., BECK, E., Servais, S., BETEA, D., CAERS, J., DE PRIJCK, B., & BEGUIN, Y. (2012). Panhypopituitarism and diabetus insipidus in a patient with primary central nervous system lymphoma. Leukemia and Lymphoma, 53 (12), 2515-16.

SERVAIS, S., & Baron, F. (2012). Allogreffe de cellules souches hématopoïétiques après conditionnements réduits ("minigreffes") comme traitement de certaines pathologies hématologiques malignes. Onco: Revue Multidisciplinaire d'Oncologie, 6, 6-12.

VERTENOEIL, G., SERVAIS, S., & Beguin, Y. (2012). Comment j'explore... une fièvre d'origine indéterminée chez le patient adulte ? Revue Médicale de Liège, 67 (7-8), 391-397.

Belle, L., Baron, F., Bruck, F., Hannon, M., Servais, S., Beguin, Y., & BRIQUET, A. (2011). Despite Inhibitory Effects on Normal Hematopoiesis in Vitro, Imatinib and Nilotinib do not Prevent Engraftment of Human CD34+ HSCs in immunodeficient NSG Mice. Poster session presented at 26th General Meeting of the Belgian Hematological Society.

SERVAIS, S., Baron, F., & Beguin, Y. (2011). Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning. Transfusion and Apheresis Science, 44, 205-210. doi:10.1016/j.transci.2011.01.019

Servais, S., Beguin, Y., & Baron, F. (2011). Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation (HSCT). Belgian Journal of Hematology, 2, 3-9.

SERVAIS, S., Hannon, M., Daulne, C., Gothot, A., Beguin, Y., & Baron, F. (2011). Longitudinal Monitoring of Immune Reconstitution After Allogeneic Peripheral Blood Stem Cell Transplantation (HSCT): Impact of T Cell Depletion of the Graft. Belgian Journal of Hematology, Abstracts book (Supplement of 26th General Meeting of the Belgian Hematological Society), 31.

Servais, S., Caers, J., Warling, O., Frusch, N., Baron, F., De Prijck, B., & Beguin, Y. (2010). Enteroviral meningoencephalitis as complication of Rituximab therapy in a patient treated for diffuse large B-cell lymphoma. British Journal of Haematology, 150 (3), 379-381. doi:10.1111/j.1365-2141.2010.08202.x

Servais, S., Willems, E., Beguin, Y., & Baron, F. (2010). Maladie du greffon contre l'hôte chronique : une prise en charge multidisciplinaire. Revue Médicale de Liège, 65, 81-87.

Beguin, Y., Maertens, J., DE PRIJCK, B., Schots, R., Frère, P., Bonnet, C., HAFRAOUI, K., WILLEMS, E., Vanstraelen, G., LEJEUNE, M., SERVAIS, S., THeunissen, K., Fillet, G., & Baron, F. (2009). A prospective randomized multicenter trial of darbepoetin-alfa and I.V. iron administration after autologous hematopoietic stem cell transplantation. Poster session presented at 24th General Meeting of the Belgian Hematological Society, Oostende, Belgium.

Servais, S., Ansseau, M., Mikolajczak, G., & Desseilles, M. (2008). L'électroconvulsivothérapie en 2008. Revue Médicale de Liège, 63, 404-410.